Keywords: b-ms, otsuka, abilify, launched, eu, bristol-myers, squibb
B-MS and Otsuka's Abilify launched in EU
Article | 28 June 2004
Bristol-Myers Squibb and Otsuka Pharmaceutical have announced, at the annual meeting of the Collegium Internationale Neuro-Psychopharmacologicum, that the antipsychotic Abilify ( ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Australia's pharma industry applauds R&D regulatory reform
